Search clinical trials for: Anti-PD1 antibody, nimotuzumab and capecitabine

Total 3235 results

Bio-Thera Solutions
Sun Yat-sen University

Recruiting

BAT7104 Injection in Patients With Advanced Malignant Tumors.

Advanced Malignant Tumor

China
Affiliated Cancer Hospital & Institute of Guangzhou...

Not yet recruiting

HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis

Gastric Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma

Sarcoma, Soft Tissue

China
Capital Medical University

Terminated

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Cancer | Mesothelioma, Malignant

China
Beijing Tongren Hospital

Recruiting

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma

China
Hangzhou Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma

Esophageal Neoplasms | Esophageal Diseases

China
M.D. Anderson Cancer Center

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Locally Advanced Angiosarcoma | Metastatic Angiosarcoma | Recurrent Angiosarcoma

United States
Anwita Biosciences
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 1 First-in-human Study of JS014

Lymphoma | Solid Tumor, Adult | Neoplasm Malignant | Neoplasm, Experimental

Taiwan
The First Affiliated Hospital of Guangzhou Medical...

Unknown

The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.

Multiple Primary Lung Cancers

China
Genentech, Inc.
BioNTech SE

Active, not recruiting

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Melanoma | Head and Neck Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | Renal Cancer | Other Solid Cancers

United States, Belgium, Sweden, Germany, Canada, Spain, United Kingdom, Netherlands
Seoul National University Hospital

Completed

MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
Dragonboat Biopharmaceutical Company Limited
Fudan University

Recruiting

the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors

Bladder Cancer | Renal Carcinoma | Advanced Penile Carcinoma

China
Zhejiang University

Recruiting

Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

Pancreatic Cancer

China
Capital Medical University

Completed

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Cancer | Metastatic Cancer | Abdominal Cancer | Pelvic Cancer | Liver Metastases | Peritoneal Metastases

China
Shanghai Henlius Biotech

Not yet recruiting

Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma

Solid Tumor, Adult Lymphoma
Henlix, Inc

Terminated

A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

Taiwan
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Gastric Cancer
Centre Hospitalier Universitaire de Besancon

Recruiting

Biomedicines and Bacterial Translocation in Spondyloarthritis (TEARE-BIO)

Axial Spondyloarthritis

France
Fundacion para la Investigacion Biomedica del Hospital...

Recruiting

Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy

Lung Cancer

Spain
Sinocelltech Ltd.

Not yet recruiting

Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers

Autoimmune Disease

Australia
Assistance Publique - Hôpitaux de Paris
Chugai Pharmaceutical

Completed

Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis (TOCITAKA)

TAKAYASU ARTERITIS

France
National Institute of Dental and Craniofacial Research...

Terminated

Pilot Study of Raptiva to Treat Sjogren's Syndrome

Sjogren's Syndrome

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors (IUNU-RC)

Non-clear Renal Cell Carcinoma

China
West China Hospital

Recruiting

Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC

Immunotherapy | SBRT | Stage IV HCC

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma (SHR-1210)

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Hepatocellular Carcinoma

China
Jacobio Pharmaceuticals Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

Advanced Melanoma | Kidney Cancer Stage Iv

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

Bladder Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Metastatic Melanoma | Advanced Melanoma

China
Samsung Medical Center

Unknown

XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy

Biliary Tract Cancer

Korea, Republic of
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Relapsed/Refractory Peripheral T-cell Lymphoma

China
National Cancer Institute (NCI)
NRG Oncology

Completed

Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage II Pancreatic Cancer

United States
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States, France, United Kingdom, Singapore, Korea, Republic of, Germany
OncoC4, Inc.

Not yet recruiting

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

Advanced Solid Tumor

United States
Sinocelltech Ltd.

Not yet recruiting

Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis

Axial Spondyloarthritis

Turkey
Shanghai Henlius Biotech

Completed

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma

Lymphoma | Solid Tumor, Adult

China
Leiden University Medical Center
Radboud University Medical Center; AstraZeneca; University Medical Center Groningen and other collaborators

Active, not recruiting

Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer (DOMEC)

Uterine Neoplasms | Endometrial Neoplasms | Endometrium Cancer

Netherlands
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

Australia
Sun Yat-sen University
Fudan University; Liaoning Tumor Hospital & Institute

Active, not recruiting

PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer

Colorectal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer

Breast Cancer

China
IRCCS San Raffaele
Regione Lombardia

Completed

Second Line Therapy in Advanced Biliary Tract Cancer (BIT-2)

Biliary Tract Cancer

Italy
AstraZeneca

Completed

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Pancreatic Cancer

United States, Bulgaria, Hungary, Romania, Australia
HuniLife Biotechnology, Inc.

Recruiting

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001

Idiopathic Pulmonary Fibrosis

Taiwan
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Multiple Myeloma

United States
Providence Health & Services
MedImmune LLC

Terminated

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

United States
Asan Medical Center
Seoul National University Bundang Hospital; Severance Hospital; Hallym University... and other collaborators

Recruiting

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

Gastric Cancer, Adjuvant Chemotherapy, XO

Korea, Republic of
Megan Daly, MD
EMD Serono

Completed

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

Metastatic Non-small Cell Lung Cancer (NSCLC)

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

Study of JS001 in Participants With Advanced Solid Tumors

Solid Tumors

China
Livzon Pharmaceutical Group Inc.

Completed

LZM009 to Treat Patients With Advanced Solid Tumors

Solid Tumor

United States

Search clinical trials for: Anti-PD1 antibody, nimotuzumab and capecitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations